Starfish Innovations is an investment fund and commercialization hub that seeks to accelerate breakthroughs in regenerative medicine. Founded in 2016 by the Leiden University Medical Centre (LUMC), we have been able to build a strong early-stage pipeline of regenerative medicine technologies through our direct access to the promising science at LUMC as well as our global network of academic institutions and industry alike.
Starfish are famous for their ability to regenerate their limbs. In fact,
a few species can
regenerate a whole new
body from just a single arm.
Latest press release
May 27, 2021
Utrecht, The Netherlands – NTrans Technologies (NTrans), a leader in gene editing technologies, today announced a Series A investment of 2 million Euros, led by Essential Investments, together with BOP Capital, Utrecht Health Seed Fund, and Starfish Innovations. Through this investment, NTrans aims to advance the development of its gene editing-based therapy for Duchenne Muscular Dystrophy (DMD). The funds will be used to demonstrate preclinical efficacy and safety of the therapy in DMD disease models, in preparation for its progression to the clinic.